Use of Selexipag in a Teenage Patient with Pulmonary Arterial Hypertension

Overview

Journal Ann Pediatr Cardiol

Specialty Cardiology & Vascular Diseases

Date 2021 Mar 8

PMID 33679065

Authors

Nathalie Jeanne Magioli Bravo-Valenzuela

Flavia Navarro

Socrates Pereira Silva

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin pathway drug and is a highly selective IP prostacyclin receptor agonist with vasodilatory and antiproliferative effects. We report the case of a teenage patient with idiopathic PAH who presented in World Health Organization functional Class IV and showed no clinical improvement with dual therapy. We added oral selexipag to the treatment regimen and observed substantial improvement in her quality of life at the short-time follow-up. Despite the lack of childhood data regarding the use of selexipag in pediatric patients with PAH, the use of this drug in the current teenage patient improved her quality of life and exercise capacity.

References

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

Whittle B, Silverstein A, Mottola D, Clapp L . Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012; 84(1):68-75. DOI: 10.1016/j.bcp.2012.03.012. View

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

Barst R, Rubin L, McGoon M, Caldwell E, Long W, LEVY P . Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994; 121(6):409-15. DOI: 10.7326/0003-4819-121-6-199409150-00003. View

Rosenzweig E, Abman S, Adatia I, Beghetti M, Bonnet D, Haworth S . Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2018; 53(1). PMC: 6351335. DOI: 10.1183/13993003.01916-2018. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Hansmann G, Meinel K, Bukova M, Chouvarine P, Wahlander H, Koestenberger M . Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. J Heart Lung Transplant. 2020; 39(7):695-706. DOI: 10.1016/j.healun.2020.03.029. View

Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel M . Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther. 2012; 343(3):547-55. DOI: 10.1124/jpet.112.197152. View

Levy M, Del Cerro M, Nadaud S, Vadlamudi K, Colgazier E, Fineman J . Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol. 2018; 264:153-157. DOI: 10.1016/j.ijcard.2018.03.067. View

10.

Ivy D, Doran A, Smith K, Mallory Jr G, Beghetti M, Barst R . Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008; 51(2):161-9. PMC: 3125969. DOI: 10.1016/j.jacc.2007.09.031. View

11.

Gallotti R, Drogalis-Kim D, Satou G, Alejos J . Single-Center Experience Using Selexipag in a Pediatric Population. Pediatr Cardiol. 2017; 38(7):1405-1409. DOI: 10.1007/s00246-017-1677-7. View

12.

Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J . Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. Am J Cardiovasc Drugs. 2015; 15(3):195-203. PMC: 4452035. DOI: 10.1007/s40256-015-0117-4. View

13.

Morrison K, Ernst R, Hess P, Studer R, Clozel M . Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther. 2010; 335(1):249-55. DOI: 10.1124/jpet.110.169748. View

14.

Barst R, Maislin G, Fishman A . Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999; 99(9):1197-208. DOI: 10.1161/01.cir.99.9.1197. View

15.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40(4):780-8. DOI: 10.1016/s0735-1097(02)02012-0. View

16.

Abman S, Hansmann G, Archer S, Ivy D, Adatia I, Chung W . Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015; 132(21):2037-99. DOI: 10.1161/CIR.0000000000000329. View

17.

Yung D, Widlitz A, Rosenzweig E, Kerstein D, Maislin G, Barst R . Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004; 110(6):660-5. DOI: 10.1161/01.CIR.0000138104.83366.E9. View

18.

Mubarak K . A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2009; 104(1):9-21. DOI: 10.1016/j.rmed.2009.07.015. View

19.

Peacock A, Murphy N, McMurray J, Caballero L, Stewart S . An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104-9. DOI: 10.1183/09031936.00092306. View

20.

McGoon M, Gutterman D, Steen V, Barst R, McCrory D, Fortin T . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):14S-34S. DOI: 10.1378/chest.126.1_suppl.14S. View